Accessibility help Skip to navigation Skip to content Skip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Manage cookies
Accept & continue
  • Sign In
  • Subscribe
Open drawer menu Open search bar
Financial Times
myFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
    Most Read
    • Labour vows to nationalise BT’s Openreach network
    • Xi ratchets up the pressure on Hong Kong to quell the violence
    • Trump accused of intimidation as Ukraine envoy testifies
    • Will Jeremy Corbyn’s spending plans trigger a crisis for the UK economy?
    • Trump associate Roger Stone convicted of lying to Congress
  • US
    Sections
    • US Home
    • US Economy
    • US Politics & Policy
    • US Companies
    Most Read
    • Amazon strikes back at Trump over $10bn Jedi contract
    • Wikipedia co-founder Jimmy Wales launches Twitter and Facebook rival
    • Lloyd Blankfein fires back at Elizabeth Warren over wealth tax video
    • Trump accused of intimidation as Ukraine envoy testifies
    • Five things I’ve learnt about saving the world
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Lloyd Blankfein fires back at Elizabeth Warren over wealth tax video
    • City fund managers call for rethink of capitalism
    • Saudi officials ‘unhappy’ with foreign demand for Aramco IPO
    • Why Apple is aiming to hire former HBO chief Richard Plepler
    • How Warhammer won battle of ‘hobby stocks’ for Games Workshop
  • Tech
  • Markets
    Sections
    • Markets Home
    • fastFT
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    Most Read
    • Will Jeremy Corbyn’s spending plans trigger a crisis for the UK economy?
    • Fingers point at hedge funds after Japan bond sell-off
    • The importance of an inverted yield curve is overrated
    • Investors pull money out of US stock and junk bond funds
    • Five market axioms that can no longer be relied upon
  • Graphics
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Instant Insight
    • Lex
    • Alphaville
    • Obituaries
    • Letters
    Most Read
    • Do the Irish want unification?
    • The importance of an inverted yield curve is overrated
    • Why the US economy isn’t as competitive or free as you think
    • Privacy uproar shows Google cloud business has a trust problem
    • OK boomer, who’s up for a generational showdown?
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    Most Read
    • Stephen Badger: Balancing profit with creating value for society
    • Five ways to look as though you care about women at work
    • FT business books of the month: November edition
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Five things I’ve learnt about saving the world
    • Inside Athletic Bilbao: the football club playing by their own rules
    • Do the Irish want unification?
    • Rahm Emanuel: ‘There is more to us than our divisions’
    • OK boomer, who’s up for a generational showdown?
  • How to Spend It
  • Sign In
  • Subscribe
Menu Search
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Graphics
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
  • Sign In
  • Subscribe

Get a fresh start.

Get a fresh start.
Choose your FT trial

Hannah Kuchler

US pharma and biotech correspondent
Hannah Kuchler reports on pharma, biotech and healthcare. After covering Silicon Valley for over five years, she's now focusing on how technology is transforming our health.
Email Hannah Kuchler @hannahkuchler (link opens in a new browser window)
Email Hannah Kuchler @hannahkuchler (link opens in a new browser window)

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Thursday, 14 November, 2019
    Apple Inc
    Apple launches app in push to gather users’ health data

    Company hopes millions of users will opt in for array of medical studies

  • Thursday, 7 November, 2019
    Teva Pharmaceutical Industries Ltd
    Teva puts further $468m aside for opioid settlements

    Israeli drugmaker reports widening quarterly loss but lifts outlook

  • Tuesday, 5 November, 2019
    Walgreens Boots Alliance Inc
    Walgreens Boots Alliance explores $70bn buyout

    Long-shot deal for pharmacy behemoth would be the largest private equity takeover ever

  • Monday, 4 November, 2019
    Stryker Corp
    US medical device maker Stryker to buy Wright Medical

    $5.4bn deal boosts group’s exposure to orthopaedics market

  • Wednesday, 30 October, 2019
    Johnson & Johnson Co Inc
    J&J says testing shows no asbestos in baby powder

    Shares rise almost 4% as it pushes back on claims at centre of thousands of lawsuits

  • Tuesday, 29 October, 2019
    Amgen Inc
    Amgen raises 2019 forecast despite competitive pressures
  • Tuesday, 29 October, 2019
    Pharmaceuticals sector
    Pfizer and Merck raise guidance on strong China growth

    Rosier results come as US drugmakers face pressure on prices in domestic market

  • Tuesday, 29 October, 2019
    Merck & Co Inc
    Merck results lifted by strong sales of cancer drug

    Pharmaceutical company also reports boost from vaccine targeting human papillomarivus

  • Wednesday, 23 October, 2019
    Eli Lilly & Co
    Eli Lilly raises earnings guidance as new drugs boost sales

    Pharmaceuticals company said revenue driven by selling more drugs, not raising prices

  • Promoted Content
  • Wednesday, 23 October, 2019
    AnalysisBiogen Idec Inc
    Alzheimer’s drug revival gives hope to millions

    Biogen says seeking approval for aducanumab hails ‘turning point’ in fight against disease

  • Tuesday, 22 October, 2019
    Biogen Idec Inc
    Biogen shares soar on plan to seek Alzheimer’s drug approval

    Biotech group says new analysis shows benefits of aducanumab when taken at a high dose

  • Monday, 21 October, 2019
    US opioid epidemic
    Drug groups and US states propose $48bn opioid deal

    Four plaintiffs aim to persuade others to sign on to framework

  • Monday, 21 October, 2019
    US opioid epidemic
    Drug groups head off opioid trial with $260m settlement

    Teva and distributors’ deal came as first federal trial on US addiction crisis was due to open

  • Friday, 18 October, 2019
    US opioid epidemic
    US opioid trial to go ahead after settlement talks fail

    First federal lawsuit to proceed after local governments call offer ‘inadequate’

  • Friday, 18 October, 2019
    Retail & Consumer industry
    J&J recalls batch of baby powder after asbestos find

    Company already faces litigation over allegations that tainted talcum powder caused cancer

  • Tuesday, 15 October, 2019
    Johnson & Johnson Co Inc
    J&J boosts outlook despite uncertainty over legal costs

    Third-quarter sales exceed expectations as growth in pharma division provides succour

  • Tuesday, 24 September, 2019
    Amazon.com
    Amazon rolls out new health technology for employees

    Move is latest example of company experimenting on how to improve service and cut costs

  • Friday, 20 September, 2019
    Special ReportRevitalised Cities: Tampa and St Petersburg
    Simulation centre prepares medics for war and disaster

    Tampa unit replicates extreme environments and injuries to help hone skills

  • Friday, 20 September, 2019
    Special ReportRevitalised Cities: Tampa and St Petersburg
    Business accelerator aims to drive Florida-Israel links

    Tampa business hub tries to attract Israeli start-ups in big local industries

  • Friday, 20 September, 2019
    Special ReportRevitalised Cities: Tampa and St Petersburg
    Tampa cancer centre’s expertise draws biotech start-ups

    Moffitt’s cutting-edge reputation is creating a cluster of specialist companies

  • Friday, 20 September, 2019
    World3 min
    Why US citizens are crossing into Canada and Mexico to buy insulin

    Democratic presidential hopeful joins a group of diabetics crossing the border to buy cheaper prescription drugs

  • Thursday, 19 September, 2019
    FT Magazine
    Why prescription drugs cost so much more in America

    The US spends more per capita on medication than anywhere else in the world. It’s a key electoral issue

  • Monday, 16 September, 2019
    Purdue Pharma LP
    Purdue Pharma files for bankruptcy

    Opiod maker owned by Sackler family has yet to reach deal with all attorneys-general

  • Friday, 13 September, 2019
    AnalysisTobacco
    Vaping fears cast cloud over US tobacco industry

    Companies brace for possible crackdown as concerns grow over spike in lung disease

  • Wednesday, 11 September, 2019
    Purdue Pharma LP
    Purdue reaches preliminary opioid deal with several states

    New York, Pennsylvania and Washington among those to rebuff settlement

Previous You are on page 1 Next

Useful links

Support

View Site Tips Help Centre About Us Accessibility myFT Tour Careers

Legal & Privacy

Terms & Conditions Privacy Cookies Copyright Slavery Statement & Policies

Services

FT Live Share News Tips Securely Individual Subscriptions Group Subscriptions Republishing Contracts & Tenders
Executive Job Search Advertise with the FT Follow the FT on Twitter FT Transact Secondary Schools

Tools

Portfolio Today's Newspaper (ePaper) Alerts Hub MBA Rankings
Enterprise Tools News feed Newsletters Currency Converter
More from the FT Group
Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2019. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
  • US
    • US Economy
    • US Politics & Policy
    • US Companies
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • fastFT
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
  • Graphics
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Instant Insight
    • Lex
    • Alphaville
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • EM Squared
  • Lunch with the FT
  • FT Globetrotter
  • Tech Scroll Asia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In